Canada markets closed

Defence Therapeutics Inc. (DTC.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
5.80+0.20 (+3.57%)
At close: 03:13PM EST
Full screen
Loading interactive chart...
  • Newsfile

    Defence Therapeutics Vaccines and Program Development

    Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform. The core of Defence Therapeutics platform is its AccumTM technology, which enables precision delivery of proteins of pharmacological int

  • Newsfile

    Defence Therapeutics Cancer Vaccine AccuVac-D001 Manufacturing Targets Melanoma and Breast Cancer

    Vancouver, British Columbia--(Newsfile Corp. - November 23, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the establishment of an agreement with the Lady Davis Institute cell processing center (CPC) to initiate manufacturing of its AccumTM DC cancer vaccine candidate AccuVAC-D001. This agreement immediately positions Defence's vac

  • Newsfile

    Defence Therapeutics Appoints Dr. Riam Shammaa to Its Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - November 9, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on the development of next generation cancer therapeutics and infectious disease vaccines is pleased to announce the appointment of Dr. Riam Shammaa to its board of directors, effective immediately. Dr. Riam Shammaa, MD, is a pioneer scientist in the fields of cell therapy and biologics and holds ...